Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-Ex PET in metastatic breast cancer
2024-512721-89-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan and 68Ga-ABY-025 in breast cancer, sponsored by Karolinska University Hospital. Planned start May 2025; status: authorised.
02
Drugs
trastuzumab deruxtecan68Ga-ABY-025
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512721-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512721-89-00.